Long-term cost-effectiveness of insertion of a biological mesh during stoma-site closure: 5–8-year follow-up of the ROCSS randomized controlled trial
British Journal of Surgery · 2024
DOI: 10.1093/bjs/znae159 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Surgery, 2024. Verfasst von Reinforcement of Closure of Stoma Site (ROCSS) Collaborative and West Midlands Research Collaborative. Hauptthemen laut MEDLINE: Surgical Mesh, Cost-Benefit Analysis, Quality of Life, Incisional Hernia. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Institute for Health Research.
Abstract (Originalsprache)
Background
The original ROCSS trial demonstrated a significant reduction in clinically detectable incisional hernias at 2 years in patients receiving prophylactic biological mesh during stoma closure. ROCSS-Ex was designed to investigate the 5–8-year cost-effectiveness of mesh in the surviving cohort using an abdominal wall–specific quality of life score.
Methods
Eligible participants from original UK centres were identified. The primary outcome (abdominal wall–specific quality of life) was measured using the HerQLes score and EQ-5D-5L. Assessors remained blind to patients’ original allocation, even if the patient was aware of their treatment.
Results
Of the original 790 patients, 598 were available for long-term follow-up. HerQLes scores were available for 396 patients (no mesh: 191, mesh: 205). There was no difference in primary outcome between the two groups (mean difference of 1.48, 95% c.i. (−2.35, 5.32), P = 0.45) and no cost benefit of routine insertion of prophylactic biological mesh across the entire cohort in the long term. However, patients who received mesh experienced significantly fewer stoma site complications within the first 3 years after reversal and needed fewer surgical reinterventions (32 versus 54 for the no mesh group; incidence rate ratio of 0.55, 95% c.i. (0.31, 0.97), P = 0.04).
Conclusions
ROCSS-Ex has shown equivocal outcomes for prophylactic mesh insertion versus standard repair on abdominal wall–specific quality of life 5–8 years after surgery. As most reinterventions occurred within the first 3 years post-surgery, there may be a role for prophylactic mesh in a subset of patients who would be most adversely affected by repeated surgery early on. Trial Registration ISRCTN25584182 (http://www.clinicaltrials.gov).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Förderung
- National Institute for Health Research
Zitieren
APA
Reinforcement of Closure of Stoma Site (ROCSS) Collaborative and West Midlands Research Collaborative (2024). Long-term cost-effectiveness of insertion of a biological mesh during stoma-site closure: 5–8-year follow-up of the ROCSS randomized controlled trial. British Journal of Surgery. https://doi.org/10.1093/bjs/znae159
Vancouver
Reinforcement of Closure of Stoma Site (ROCSS) Collaborative and West Midlands Research Collaborative. Long-term cost-effectiveness of insertion of a biological mesh during stoma-site closure: 5–8-year follow-up of the ROCSS randomized controlled trial. British Journal of Surgery. 2024. doi:10.1093/bjs/znae159
BibTeX
@article{ReinforcementofClosureofStomaSiteROCSSCollaborativeandWestMidlandsResearchCollaborative2024,
author = {Reinforcement of Closure of Stoma Site (ROCSS) Collaborative and West Midlands Research Collaborative, Reinforcement of Closure of Stoma Site (ROCSS) Collaborative and West Midlands Research Collaborative},
title = {Long-term cost-effectiveness of insertion of a biological mesh during stoma-site closure: 5–8-year follow-up of the ROCSS randomized controlled trial},
journal = {British Journal of Surgery},
year = {2024},
doi = {10.1093/bjs/znae159}
}
EUVIMED